Evolving knowledge in neuro-urology

**Location:** Room Berlin, North Hall (Level 1)

**Chairs:**
- S. Charalampous, Limassol (CY)
- T.M. Kessler, Zurich (CH)
- T.L.C. Kuo, Singapore (SG)

**Aims and objectives of this session**
Neurological diseases can cause considerable urological problems. In this session recent advances are discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**157**

*The use of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease*

By: Gubbiotti M., Rossi De Vermandois J., Turco M., Giannantoni A.

Institutes: University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy

---

**158**

*Comparison of intradetrusor injections of botulinum toxin A in adult patients with spina bifida and in patients with spinal cord injury: A multicenter study*

By: Peyronnet B., Hascoet J., Roumiguie M., Castel-Lacanale E., Marque P., Manunta A., Game X.

Institutes: CHU Rennes, Dept. of Urology, Rennes, France, CHU Toulouse, Dept. of Urology, Toulouse, France, CHU Toulouse, Dept. of Physical Medicine and Rehabilitation, Toulouse, France

---

**159**

*Clinical profile of amyotrophic lateral sclerosis patients with lower urinary tract symptoms and neurogenic bladder: A cross-sectional study*

By: Arlandis S., Vázquez-Costa J.F., Martínez-Cuenca E., Hervás D., Sevilla T., Broseta Rico E.

Institutes: La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, La Fe, University and Polytechnic Hospital, Dept. of Neurology, Valencia, Spain, Instituto De Investigación Sanitaria La Fe, Dept. of Biostatistics, Valencia, Spain

---

**160**

*Frontal lobe function correlates with one-year incidence of urinary incontinence in elderly with Alzheimer disease*

By: Yoshida M., Sugimoto T., Ono R., Murata S., Saji N., Niida S., Toba K., Sakurai T.

Institutes: National Center For Geriatrics and Gerontology, Dept. of Urology, Obu, Japan, National Center For Geriatrics and Gerontology, Center For Comprehensive Care and Research On Memory Disorders, Obu, Japan, Kobe University, Graduate School of Health Sciences, Dept. of Community Health Sciences, Kobe, Japan, National Center For Geriatrics and Gerontology, Medical Genome Center, Obu, Japan

---

**161**

*Feasibility, morbidity and functional results of robotic supratrigonal cystectomy with augmentation ileocystoplasty*


Institutes: Nantes University Hospital, Dept. of Urology, Nantes, France

---

**162**

*Intra detrusor injections of botulinum toxin type A in children with spina bifida: A multicenter study*

By: Hascoet J., Forin V., Baron M., Capon G., Prudhomme T., Allenet C., Tournier S., Maurin
Long-term outcome of adenosine A2A receptor antagonist on lower urinary tract symptoms in male Parkinson's disease patients

By: Kitta T.1, Yabe I.2, Kanno Y.1, Ouchi M.1, Moriya K.1, Takahashi I.2, Matsushima M.2, Sasaki H.2, Shinohara N.1

Institutes: Hokkaido University School of Medicine, Dept. of Urology, Sapporo, Japan,1 Hokkaido University School of Medicine, Dept. of Neurology, Sapporo, Japan

Can we avoid bladder augmentation in case of failure of a first intradetrusor botulinum toxin injections in patients with spinal dysraphism?


Institutes: CHU Rennes, Dept. of Urology, Rennes, France, 2Tenon Hospital, Dept. of Neurourolgy, Paris, France, 3Clinique Saint-Augustin, Dept. of Neurourolgy, Bordeaux, France, 4CHU Lausanne, Dept. of Neurourolgy, Lausanne, France, 5Raymond Poinçaré Hospital, Dept. of Neurourolgy, Garches, France, 6CHU Bordeaux, Dept. of Urology, Bordeaux, France, 7CHU Toulouse, Dept. of Urology, Toulouse, France, 8CHU Nantes, Dept. of Urology, Nantes, France, 9CHU Marseille, Dept. of Urology, Marseille, France, 10CHU Lille, Dept. of Urology, Lille, France, 11CHU Tours, Dept. of Urology, Tours, France, 12CHU Rouen, Dept. of Urology, Rouen, France, 13CHU Strasbourg, Dept. of Urology, Strasbourg, France, 14CHU Rennes, Dept. of Physical Medicine and Rehabilitation, Rennes, France, 15Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France

Combined treatment of DDAVP and mirabegron represents an effective treatment of neurogenic detrusor overactivity in patients with multiple sclerosis

By: Zachariou A.1, Filiponi M.2, Dimitriadis F.1, Takenaka A.3, Sofikitis N.1

Institutes: Ioannina University School of Medicine, Dept. of Urology, Ioannina, Greece, 2Elpis Hospital, Dept. of Urology, Volos, Greece, 3Tottori University School of Medicine, Dept. of Urology, Tottori, Japan

Detrusor acontractility after acute spinal cord injury: Myth or reality

By: Bywater M., Tornic J., Mehnert U., Kessler T.

Institutes: University Hospital Balgrist, Dept. of Neuro Urology, Zürich, Switzerland

High EDSS can predict risk for upper tract damage in patients with multiple sclerosis

By: Schneider M.P.1, Ineichen B.1, Hagenbuch N.2, Linnebank M.3, Kessler T.4

Institutes: University Hospital of Zürich, Dept. of Neuro-Urology, Zürich, Switzerland, 2Biostatistics and Prevention Institute, Dept. of Biostatistics, Zürich, Switzerland, 3University Hospital Zürich, Dept. of Neurology, Zürich, Switzerland, 4Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland

Influence of botulinum toxin type A on urodynamic parameters and sexual function in men with neurogenic detrusor overactivity

By: Sivkov A.1, Romikh V.2, Pantelev V.3, Zaharchenko A.2, Arkhieev A.2, Apolikhin O.1, Kaprin A.3

Institutes: Research Institute of Urology and Interventional Radiology N.a. Lopaktn - Branch of Fsbi Nmrrc, Moscow, Russia, 2Research Institute of Urology and Interventional Radiology N.a. Lopaktn - Branch of Fsbi Nmrrc, Neurourology and Urodynamics, Moscow, Russia, 3Fsbi Nmrrc, Neurourology and Urodynamics, Moscow, Russia
Moscow, Russia